Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Other financing activities (2016 - 2025)

Historic Other financing activities for Surgery Partners (SGRY) over the last 12 years, with Q3 2025 value amounting to -$600000.0.

  • Surgery Partners' Other financing activities fell 40000.0% to -$600000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 9544.55%. This contributed to the annual value of $14.9 million for FY2024, which is 3868.31% down from last year.
  • Latest data reveals that Surgery Partners reported Other financing activities of -$600000.0 as of Q3 2025, which was down 40000.0% from $6.6 million recorded in Q2 2025.
  • Over the past 5 years, Surgery Partners' Other financing activities peaked at $35.4 million during Q4 2023, and registered a low of -$27.1 million during Q3 2021.
  • In the last 5 years, Surgery Partners' Other financing activities had a median value of -$600000.0 in 2025 and averaged $2.0 million.
  • Data for Surgery Partners' Other financing activities shows a peak YoY increase of 167500.0% (in 2021) and a maximum YoY decrease of 710000.0% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Surgery Partners' Other financing activities stood at -$14.0 million in 2021, then skyrocketed by 325.0% to $31.5 million in 2022, then rose by 12.38% to $35.4 million in 2023, then crashed by 100.56% to -$200000.0 in 2024, then tumbled by 200.0% to -$600000.0 in 2025.
  • Its Other financing activities was -$600000.0 in Q3 2025, compared to $6.6 million in Q2 2025 and -$3.5 million in Q1 2025.